PL2365828T3 - Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów - Google Patents

Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów

Info

Publication number: PL2365828T3
Authority: PL; Poland
Prior art keywords: growth factor; monoclonal antibodies; factor receptor; fibroblast growth; fibroblast
Prior art date: 2008-11-07

Application number

PL09825523T

Other languages

English (en)

Inventor

Kyung Jin Kim

Wei-Meng Zhao

Hangil Park

Maximiliano Vasquez

Original Assignee

Galaxy Biotech Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-07

Filing date

2009-11-06

Publication date

2015-04-30

2009-11-06 Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc

2015-04-30 Publication of PL2365828T3 publication Critical patent/PL2365828T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL09825523T 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów PL2365828T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US11268608P	2008-11-07	2008-11-07
US16487009P	2009-03-30	2009-03-30
PCT/US2009/063647 WO2010054265A2 (en)	2008-11-07	2009-11-06	Monoclonal antibodies to fibroblast growth factor receptor 2
EP09825523.5A EP2365828B1 (en)	2008-11-07	2009-11-06	Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (1)

Publication Number	Publication Date
PL2365828T3 true PL2365828T3 (pl)	2015-04-30

Family

ID=42153600

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL09825523T PL2365828T3 (pl)	2008-11-07	2009-11-06	Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
PL17191118T PL3290052T3 (pl)	2008-11-07	2009-11-06	Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
PL14188785T PL2842573T3 (pl)	2008-11-07	2009-11-06	Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL17191118T PL3290052T3 (pl)	2008-11-07	2009-11-06	Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
PL14188785T PL2842573T3 (pl)	2008-11-07	2009-11-06	Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów

Country Status (20)

Country	Link
US (8)	US8101723B2 (pl)
EP (4)	EP3783024A1 (pl)
JP (8)	JP5627591B2 (pl)
KR (1)	KR101699432B1 (pl)
CN (1)	CN102131524B (pl)
AU (1)	AU2009313357B2 (pl)
BR (1)	BRPI0917315B8 (pl)
CA (2)	CA2733668C (pl)
DK (3)	DK2842573T3 (pl)
ES (3)	ES2646168T3 (pl)
HR (2)	HRP20171640T1 (pl)
HU (1)	HUE035700T2 (pl)
LT (2)	LT3290052T (pl)
MX (1)	MX2011000455A (pl)
NO (1)	NO2842573T3 (pl)
PL (3)	PL2365828T3 (pl)
PT (3)	PT2365828E (pl)
RU (1)	RU2546254C9 (pl)
SI (2)	SI3290052T1 (pl)
WO (1)	WO2010054265A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9260525B2 (en)	2008-02-04	2016-02-16	Xiao-Jia Chang	Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A2 (en) *	2008-02-04	2009-08-13	Attogen Inc.	Inhibitors of oncogenic isoforms and uses thereof
NO2842573T3 (pl)	2008-11-07	2018-02-24
CA2800311A1 (en) *	2010-05-11	2011-11-17	Aveo Pharmaceuticals, Inc.	Anti-fgfr2 antibodies
EP2603521A4 (en) *	2010-08-12	2014-10-01	Attogen Inc	ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
CN107903325B (zh)	2011-05-16	2021-10-29	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
AR088941A1 (es)	2011-11-23	2014-07-16	Bayer Ip Gmbh	Anticuerpos anti-fgfr2 y sus usos
AU2012351685A1 (en) *	2011-12-14	2014-07-03	Seattle Genetics, Inc.	FGFR antibody drug conjugates (ADCs) and the use thereof
EA028433B1 (ru)	2012-03-08	2017-11-30	Янссен Вэксинс Энд Превеншн Б.В.	Антитело, связывающееся с вирусами гриппа b и его применение
NZ631445A (en)	2012-04-09	2017-02-24	Daiichi Sankyo Co Ltd	Anti-fgfr2 antibody
WO2014089193A1 (en) *	2012-12-04	2014-06-12	Aveo Pharmaceuticals, Inc.	Anti-fgfr2 antibodies
ES2705328T3 (es) *	2012-12-21	2019-03-22	Janssen Biotech Inc	Inmunoensayo sensible de múltiples etapas para receptores solubles de factor de crecimiento de fibroblastos
CN103145843B (zh) *	2013-02-20	2014-10-29	暨南大学	抗成纤维细胞生长因子受体的单链抗体
HK1213180A1 (zh)	2013-03-06	2016-06-30	豪夫迈‧罗氏有限公司	治疗和预防癌症药物抗性的方法
KR20250099279A (ko) *	2013-08-01	2025-07-01	파이브 프라임 테라퓨틱스, 인크.	비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
KR20160066024A (ko) *	2013-10-08	2016-06-09	다이이찌 산쿄 가부시키가이샤	항 fgfr2 항체와 타제의 조합
CN103757026B (zh) *	2013-12-20	2017-04-05	广州圣露生物技术有限公司	FGFR2b胞外段的基因序列、多肽及其应用
WO2015191986A1 (en)	2014-06-13	2015-12-17	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
CN104231079A (zh) *	2014-09-12	2014-12-24	暨南大学	一种靶向bFGF高亲和力受体结合位点的抗体及其应用
WO2016163433A1 (ja) *	2015-04-08	2016-10-13	第一三共株式会社	抗ｆｇｆｒ２抗体と他剤を含む組成物
US10881734B2 (en)	2015-04-20	2021-01-05	Daiichi Sankyo Company, Limited	Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
RU2638457C2 (ru) *	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
KR102777244B1 (ko)	2015-11-23	2025-03-11	파이브 프라임 테라퓨틱스, 인크.	암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
WO2017157305A1 (en)	2016-03-15	2017-09-21	Generon (Shanghai) Corporation Ltd.	Multispecific fab fusion proteins and use thereof
WO2018156180A1 (en)	2017-02-24	2018-08-30	Kindred Biosciences, Inc.	Anti-il31 antibodies for veterinary use
BR112019023898A2 (pt)	2017-05-16	2020-06-09	Five Prime Therapeutics Inc	método para tratamento de câncer gástrico, uso de um anticorpo e composição
EP3630818A1 (en)	2017-06-02	2020-04-08	Ablynx NV	Aggrecan binding immunoglobulins
MX2020004140A (es)	2017-10-24	2020-08-13	Magenta Therapeutics Inc	Composiciones y metodos para la eliminacion de celulas cd117+.
WO2019084067A1 (en) *	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	ANTI-CD117 ANTIBODIES AND METHODS OF USE
US10882915B2 (en)	2017-10-24	2021-01-05	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of CD117+ cells
WO2020048525A1 (en)	2018-09-07	2020-03-12	Generon (Shanghai) Corporation Ltd.	Bispecific antigen binding proteins and uses thereof
BR112021005204A2 (pt)	2018-10-05	2021-06-08	Five Prime Therapeutics, Inc.	formulações farmacêuticas e método para tratar um tumor sólido
KR20220119143A (ko) *	2019-12-24	2022-08-26	디잘 (지앙수) 파마슈티칼 씨오., 리미티드	신규한 항fgfr2b 항체
KR20220119144A (ko) *	2019-12-24	2022-08-26	디잘 (지앙수) 파마슈티칼 씨오., 리미티드	신규한 항fgfr2b 항체
EP4161566A4 (en) *	2020-06-03	2024-06-12	The Broad Institute, Inc.	ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF
CA3190569A1 (en)	2020-10-22	2022-04-28	Christopher Daly	Anti-fgfr2 antibodies and methods of use thereof
KR20230129456A (ko) *	2020-12-29	2023-09-08	선전 포워드 파머수티컬즈 코 엘티디	항-fgfr2 항체 및 이의 용도
EP4414387A4 (en) *	2021-10-08	2025-10-29	Shenzhen Forward Pharmaceuticals Co Ltd	ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE
TW202342527A (zh)	2022-02-25	2023-11-01	美商安進公司	鱗狀非小細胞肺癌之治療
CN120418288A (zh) *	2022-09-30	2025-08-01	思康睿奇(上海)药业有限公司	FGFR2b抗体及其用途
WO2024222912A1 (zh) *	2023-04-28	2024-10-31	武汉人福创新药物研发中心有限公司	抗FGFR2b单抗
AU2024277592A1 (en) *	2023-05-19	2025-11-20	Sunshine Lake Pharma Co., Ltd.	Anti-fgfr2 antibody and use thereof
WO2024255756A1 (zh) *	2023-06-13	2024-12-19	南京维立志博生物科技股份有限公司	基于共同轻链产生双特异性抗体的方法
TW202527998A (zh) *	2023-12-18	2025-07-16	大陸商山東先聲生物製藥有限公司	抗FGFR2b抗體-藥物綴合物及其應用
WO2025218662A1 (zh) *	2024-04-16	2025-10-23	杭州中美华东制药有限公司	抗成纤维细胞生长因子受体2b的抗体及其用途
WO2025232811A1 (zh) *	2024-05-09	2025-11-13	正大天晴药业集团股份有限公司	靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CA2063431C (en)	1989-07-06	2002-10-29	Lewis T. Williams	Receptors for fibroblast growth factors
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5863888A (en)	1990-07-06	1999-01-26	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Human Bek Fibroblast growth factor receptor
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DK0585287T3 (da)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6066718A (en)	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
JPH09503672A (ja) *	1993-10-14	1997-04-15	イミュネックス・コーポレーション	Ｆａｓ拮抗剤とその利用
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en)	1996-06-18	1998-01-07	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) *	1999-03-25	2003-07-31	Genesis Research And Development Corporation Limited	Fibroblast growth factor receptors and methods for their use
ATE269357T1 (de) *	1999-04-28	2004-07-15	Univ Texas	Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
JP2001302699A (ja)	2000-04-17	2001-10-31	Nichirei Corp	ヒトｋｇｆｒに対する抗体
US20020115603A1 (en)	2000-06-22	2002-08-22	Chiron Corporation	Methods and compositions for the treatment of peripheral artery disease
CA2450285C (en) *	2001-06-13	2016-08-02	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
JP2005500034A (ja)	2001-06-20	2005-01-06	プロションバイオテクリミテッド	受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
CN1671416B (zh)	2001-07-12	2013-01-02	杰斐逊·富特	超人源化抗体
WO2003063893A2 (en)	2002-01-31	2003-08-07	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Fgfr agonists
KR100493460B1 (ko) *	2002-08-29	2005-06-07	재단법인서울대학교산학협력재단	암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en)	2003-04-18	2007-05-22	Galaxy Biotech, Llc	Monoclonal antibodies to hepatocyte growth factor
EP1648998B1 (en)	2003-07-18	2014-10-01	Amgen Inc.	Specific binding agents to hepatocyte growth factor
US20070248605A1 (en)	2003-12-19	2007-10-25	Five Prime Therapetutics, Inc.	Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2005115363A2 (en)	2004-05-25	2005-12-08	Yale University	Method for treating skeletal disorders resulting from fgfr malfunction
US7890267B2 (en)	2006-03-31	2011-02-15	Ordway Research Institute	Prognostic and diagnostic method for cancer therapy
AR059922A1 (es)	2006-04-01	2008-05-07	Galaxy Biotech Llc	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2018442A2 (en) *	2006-05-12	2009-01-28	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of cancer
KR101196184B1 (ko)	2006-06-02	2012-11-01	아베오 파마슈티컬즈, 인크.	간세포 성장 인자 (ｈｇｆ) 결합 단백질
AR061171A1 (es)	2006-06-02	2008-08-06	Aveo Pharmaceuticals Inc	Proteinas de union al factor de crecimiento de hepatocitos (fch)
CA2655504A1 (en)	2006-06-15	2007-12-21	Fibron Ltd.	Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
KR101477824B1 (ko)	2006-09-29	2015-01-02	온코메드 파마슈티칼스, 인크.	암의 진단 및 치료를 위한 조성물 및 방법
JP5570218B2 (ja) *	2006-11-03	2014-08-13	ユースリーファーマゲゼルシャフトミットベシュレンクテルハフツング	Ｆｇｆｒ４抗体
CA2680046A1 (en) *	2007-03-23	2008-10-02	The Translational Genomics Research Institute	Methods of diagnosing, classifying and treating endometrial cancer and precancer
WO2009052830A1 (en)	2007-10-22	2009-04-30	Genmab A/S	Novel antibody therapies
WO2009100105A2 (en)	2008-02-04	2009-08-13	Attogen Inc.	Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en)	2008-10-10	2010-04-21	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
NO2842573T3 (pl)	2008-11-07	2018-02-24
US20120301482A1 (en)	2009-08-25	2012-11-29	National Jewish Health	Methods and compositions for treatment of lung injury

2009
- 2009-11-06 NO NO14188785A patent/NO2842573T3/no unknown
- 2009-11-06 CA CA2733668A patent/CA2733668C/en active Active
- 2009-11-06 CN CN200980132269.2A patent/CN102131524B/zh active Active
- 2009-11-06 EP EP19193727.5A patent/EP3783024A1/en active Pending
- 2009-11-06 PT PT98255235T patent/PT2365828E/pt unknown
- 2009-11-06 CA CA3166399A patent/CA3166399A1/en active Pending
- 2009-11-06 DK DK14188785.1T patent/DK2842573T3/en active
- 2009-11-06 LT LTEP17191118.3T patent/LT3290052T/lt unknown
- 2009-11-06 SI SI200932035T patent/SI3290052T1/sl unknown
- 2009-11-06 KR KR1020117002577A patent/KR101699432B1/ko active Active
- 2009-11-06 ES ES14188785.1T patent/ES2646168T3/es active Active
- 2009-11-06 JP JP2011534932A patent/JP5627591B2/ja active Active
- 2009-11-06 ES ES17191118T patent/ES2770134T3/es active Active
- 2009-11-06 EP EP17191118.3A patent/EP3290052B1/en active Active
- 2009-11-06 LT LTEP14188785.1T patent/LT2842573T/lt unknown
- 2009-11-06 HU HUE14188785A patent/HUE035700T2/en unknown
- 2009-11-06 ES ES09825523.5T patent/ES2523740T3/es active Active
- 2009-11-06 RU RU2011141890/10A patent/RU2546254C9/ru active
- 2009-11-06 SI SI200931763T patent/SI2842573T1/en unknown
- 2009-11-06 US US12/614,282 patent/US8101723B2/en active Active
- 2009-11-06 DK DK09825523.5T patent/DK2365828T3/en active
- 2009-11-06 EP EP14188785.1A patent/EP2842573B1/en active Active
- 2009-11-06 DK DK17191118.3T patent/DK3290052T3/da active
- 2009-11-06 BR BRPI0917315A patent/BRPI0917315B8/pt active IP Right Grant
- 2009-11-06 PL PL09825523T patent/PL2365828T3/pl unknown
- 2009-11-06 WO PCT/US2009/063647 patent/WO2010054265A2/en not_active Ceased
- 2009-11-06 PL PL17191118T patent/PL3290052T3/pl unknown
- 2009-11-06 AU AU2009313357A patent/AU2009313357B2/en active Active
- 2009-11-06 PT PT171911183T patent/PT3290052T/pt unknown
- 2009-11-06 PT PT141887851T patent/PT2842573T/pt unknown
- 2009-11-06 EP EP09825523.5A patent/EP2365828B1/en active Active
- 2009-11-06 PL PL14188785T patent/PL2842573T3/pl unknown
- 2009-11-06 MX MX2011000455A patent/MX2011000455A/es active IP Right Grant
2011
- 2011-10-28 US US13/284,838 patent/US8603987B2/en active Active
2013
- 2013-11-04 US US14/071,520 patent/US9382324B2/en active Active
2014
- 2014-06-04 JP JP2014115617A patent/JP6342223B2/ja active Active
2016
- 2016-06-02 US US15/172,033 patent/US9834609B2/en active Active
- 2016-08-03 JP JP2016152670A patent/JP6445496B2/ja active Active
2017
- 2017-08-10 US US15/674,385 patent/US10138301B2/en active Active
- 2017-10-26 HR HRP20171640TT patent/HRP20171640T1/hr unknown
2018
- 2018-10-18 US US16/164,530 patent/US10689448B2/en active Active
- 2018-11-29 JP JP2018223183A patent/JP6661734B2/ja active Active
2020
- 2020-01-20 HR HRP20200090TT patent/HRP20200090T1/hr unknown
- 2020-02-06 JP JP2020018719A patent/JP6960485B2/ja active Active
- 2020-05-05 US US16/867,398 patent/US20200347141A1/en not_active Abandoned
2021
- 2021-10-11 JP JP2021166672A patent/JP7301106B2/ja active Active
2023
- 2023-03-10 US US18/182,242 patent/US20230242650A1/en active Pending
- 2023-06-20 JP JP2023100475A patent/JP2023116746A/ja active Pending
2024
- 2024-11-05 JP JP2024193584A patent/JP2025032085A/ja active Pending

Also Published As

Publication number	Publication date
HK1249053A1 (en)	2018-10-26
JP2020096615A (ja)	2020-06-25
US9382324B2 (en)	2016-07-05
JP2023116746A (ja)	2023-08-22
US20180094063A1 (en)	2018-04-05
HRP20171640T1 (hr)	2018-01-12
EP3290052A1 (en)	2018-03-07
US9834609B2 (en)	2017-12-05
KR101699432B1 (ko)	2017-01-24
AU2009313357B2 (en)	2015-06-11
LT2842573T (lt)	2017-12-11
AU2009313357A1 (en)	2010-05-14
EP2365828A2 (en)	2011-09-21
DK2365828T3 (en)	2014-12-08
WO2010054265A2 (en)	2010-05-14
EP2842573A1 (en)	2015-03-04
US8603987B2 (en)	2013-12-10
JP2017019807A (ja)	2017-01-26
RU2546254C2 (ru)	2015-04-10
HRP20200090T1 (hr)	2020-04-03
US20190153105A1 (en)	2019-05-23
PL3290052T3 (pl)	2020-06-29
PT2365828E (pt)	2014-12-12
CN102131524A (zh)	2011-07-20
CA2733668A1 (en)	2010-05-14
JP2022008996A (ja)	2022-01-14
SI3290052T1 (sl)	2020-07-31
BRPI0917315B1 (pt)	2020-12-08
BRPI0917315A2 (pt)	2015-11-17
SI2842573T1 (en)	2018-01-31
JP6445496B2 (ja)	2018-12-26
MX2011000455A (es)	2011-02-25
RU2546254C9 (ru)	2015-07-10
JP6960485B2 (ja)	2021-11-05
HK1160012A1 (en)	2012-08-10
EP2365828A4 (en)	2012-06-06
US10689448B2 (en)	2020-06-23
US20160362496A1 (en)	2016-12-15
EP3290052B1 (en)	2019-12-25
BRPI0917315B8 (pt)	2021-05-25
KR20110081141A (ko)	2011-07-13
JP6342223B2 (ja)	2018-06-13
US20120134994A1 (en)	2012-05-31
EP2842573B1 (en)	2017-09-27
LT3290052T (lt)	2020-02-25
US20200347141A1 (en)	2020-11-05
PT3290052T (pt)	2020-02-06
ES2646168T3 (es)	2017-12-12
JP7301106B2 (ja)	2023-06-30
WO2010054265A3 (en)	2010-09-16
ES2770134T3 (es)	2020-06-30
CA3166399A1 (en)	2010-05-14
HUE035700T2 (en)	2018-05-28
JP2012508184A (ja)	2012-04-05
JP2025032085A (ja)	2025-03-11
EP3783024A1 (en)	2021-02-24
NO2842573T3 (pl)	2018-02-24
HK1207974A1 (en)	2016-02-19
JP5627591B2 (ja)	2014-11-19
DK2842573T3 (en)	2017-10-30
CN102131524B (zh)	2014-05-14
ES2523740T3 (es)	2014-12-01
US10138301B2 (en)	2018-11-27
CA2733668C (en)	2022-08-30
US20100196364A1 (en)	2010-08-05
JP6661734B2 (ja)	2020-03-11
US20230242650A1 (en)	2023-08-03
DK3290052T3 (da)	2020-02-03
PL2842573T3 (pl)	2018-04-30
EP2365828B1 (en)	2014-10-15
US8101723B2 (en)	2012-01-24
JP2019052165A (ja)	2019-04-04
US20140193899A1 (en)	2014-07-10
JP2014240385A (ja)	2014-12-25
PT2842573T (pt)	2017-12-04
RU2011141890A (ru)	2013-04-27

Publication	Publication Date	Title
HRP20171640T1 (hr)	2018-01-12	Monoklonska protutijela za receptor faktora rasta fibroblasta 2
IL199725A0 (en)	2010-04-15	Recombinant anti-epidermal growth factor receptor antibody compositions
IL210348A0 (en)	2011-03-31	Recombinant anti - epidermal growth factor receptor antibody compositions
HRP20181616T1 (hr)	2018-12-14	Potpuno ljudska anti-vap-1 monoklonska antitijela
ZA200807903B (en)	2010-03-31	Humanized monoclonal antibodies to hepatocyte growth factor
EP2331579A4 (en)	2013-01-23	MONOCLONAL ANTIBODIES
ZA200906345B (en)	2010-11-24	Anti-sclerostin antibodies
PL2195026T3 (pl)	2014-05-30	Przeciwciała przeciw sklerostynie
SG10201601279SA (en)	2016-03-30	Monoclonal Antibody STRO-4
IL200168A0 (en)	2010-04-15	Monoclonal anti-cxcl13 antibodies
EP2125890A4 (en)	2010-04-07	ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
SI2483309T1 (sl)	2016-10-28	Protitelesa, ki se specifično vežejo na receptor epidermalnega rastnega faktorja
PL2121758T3 (pl)	2015-02-27	Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści
ZA200905341B (en)	2010-05-26	Recombinant anti-epidermal growth factor receptor antibody compositions
TWI348915B (en)	2011-09-21	Anti-vegf monoclonal antibody
AU2006900785A0 (en)	2006-03-02	Antibodies to insulin-like growth factor I receptor